What does 2023 have in store for biotech? How can the FDA win back trust? And who came up with “XBB.1.5”?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we delve into a sweeping congressional investigation into the FDA’s approval of the latest treatment for Alzheimer’s disease and what it means for the next one. We also preview the upcoming J.P. Morgan Healthcare Conference and the biggest biotech events of 2023.
In-depth analysis of biopharma and the life sciences
Sign up for STAT+ to access in-depth analysis of biopharma, inside intelligence from Capitol Hill, the latest on medicine tech, and more. Subscribe today to start your free 30-day trial.
No comments